삼성서울병원

Ko En

혈액종양내과 홍정용 교수

진료분야
육종, 간암, 췌장암, 암정밀치료
진료일정 05 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후
진료일정 06 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
오전
오후

학력

학력
2014.08 성균관대학원 의과대학 박사학위 취득
2010.08 연세대학원 의과대학 석사학위 취득
2004.02 연세대학교 졸업

경력

경력
2020.03 ~현재 삼성서울병원 혈액종양내과 부교수
2019.03 ~ 2020.02 삼성서울병원 혈액종양내과 진료부교수
2016.03 ~ 2019.02 서울아산병원 종양내과 임상조교수
2014.03 ~ 2016.02 중앙대학교병원 혈액종양내과 임상조교수
2012.05 ~ 2014.02 삼성서울병원 혈액종양내과 임상강사
2009.03 ~ 2012.05 대한민국 육군 군의관
2005.03 ~ 2009.02 삼성서울병원 레지던트
2004.03 ~ 2005.02 신촌세브란스병원 인턴

학회활동

학회활동
2008.02 ~ 현재 대한혈액학회
2008.02 ~ 현재 종양내과학회
2005.03 ~ 현재 대한내과학회
  • CLIN TRANSL RAD ONCO 2024 10.1016/j.ctro.2024.100732 Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy Kim, K; Park, HC; Yu, JI; Park, JO; Hong, JY; Lee, KT; Lee, KH; Lee, JK; Park, JK; Heo, JS; Shin, SH; Min, JH; Kim, K; Han, IW
    View PubMed
  • INT J CLIN ONCOL 2024 10.1007/s10147-024-02506-2 Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study Oh, CR; Jeong, H; Kim, W; Lee, JS; Song, SY; Song, JS; Cho, KJ; Chung, HW; Lee, MH; Hong, JY; Lee, J; Kim, JE; Ahn, JH
    View PubMed
  • BIOMATERIALS 2024 10.1016/j.biomaterials.2024.122504 Patient-derived tumor spheroid-induced angiogenesis preclinical platform for exploring therapeutic vulnerabilities in cancer Ko, JH; Hyung, S; Heo, YJ; Jung, SM; Kim, ST; Park, SH; Hong, JY; Lim, SH; Kim, KM; Yoo, S; Li Jeon, N; Lee, JY
    View PubMed
  • NAT MED 2024 10.1038/s41591-024-02824-y Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial Kim, HD; Jung, S; Lim, HY; Ryoo, BY; Ryu, MH; Chuah, S; Chon, HJ; Kang, B; Hong, JY; Lee, HC; Moon, DB; Kim, KH; Kim, TW; Tai, D; Chew, V; Lee, JS; Finn, RS; Koh, JY; Yoo, C
    View PubMed
  • BIOMEDICINES 2023 10.3390/biomedicines11123264 Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data Lim, SH; Jung, J; Hong, JY; Kim, ST; Park, SH; Park, JO; Kim, KM; Lee, J
    View PubMed
  • CANCERS 2023 10.3390/cancers15245745 Adverse Effect of the Duration of Antibiotic Use Prior to Immune Checkpoint Inhibitors on the Overall Survival of Patients with Recurrent Gynecologic Malignancies Jung, HJ; Park, JH; Oh, J; Lee, SM; Jang, I; Hong, JY; Lee, YY; Choi, HJ
    View PubMed
  • J NATL COMPR CANC NE 2023 10.6004/jnccn.2023.7060 Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study Park, JH; Hong, JY; Shen, JJ; Han, K; Park, YS; Park, JO
    View PubMed
  • ANTICANCER RES 2023 10.21873/anticanres.16607 Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study Lim, SH; Hong, JY; Park, JO; Park, YS; Kim, ST
    View PubMed
  • CANCERS 2023 10.3390/cancers15153841 A Machine Learning Approach Using FDG PET-Based Radiomics for Prediction of Tumor Mutational Burden and Prognosis in Stage IV Colorectal Cancer Lee, H; Moon, SH; Hong, JY; Lee, J; Hyun, SH
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.6190 Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06 Sohn, BS; Kim, J; Kim, M; Hong, JY; Lee, J; Park, SE; Kim, H; Lee, HJ; Kang, EJ; Lee, SI; Lee, IH; Huh, SJ; Jo, J; Kim, HY
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.22.01740 Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study Park, JH; Hong, JY; Shen, JJ; Han, K; Park, JO; Park, YS; Lim, HY
    View PubMed
  • THER ADV GASTROENTER 2023 10.1177/17562848231170484 The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation Jeong, SY; Hong, JY; Park, JO; Park, YS; Lim, HY; Jang, JY; Jeon, Y; Kim, ST
    View PubMed
  • CLIN MOL HEPATOL 2023 10.3350/cmh.2022.0404 Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective Goh, MJ; Sinn, DH; Kim, JM; Lee, MW; Hyun, DH; Il Yu, J; Hong, JY; Choi, MS
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.251 Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response Hong, JY; Cho, HJ; Yun, KH; Lee, YH; Kim, SH; Baek, W; Kim, SK; Lee, Y; Choi, YL; Kwon, M; Kim, HS; Lee, J
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.343 Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder Kim, H; Jeong, BC; Hong, J; Kwon, GY; Kim, CK; Park, W; Pyo, H; Song, W; Sung, HH; Hong, JY; Park, SH
    View PubMed
  • LIVER CANCER 2023 10.1159/000529609 Association Between Smoking Cessation and the Risk of Cholangiocarcinoma and Ampulla of Vater Cancer: A Nationwide Cohort Study Park, JH; Hong, JY; Han, KD
    View PubMed
  • DIABETES CARE 2023 10.2337/dc22-0961 Association Between Glycemic Status and the Risk of Kidney Cancer in Men and Women: A Nationwide Cohort Study Park, JH; Hong, JY; Han, K; Shen, JJ
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.5530 Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers Kim, JE; Kim, H; Kim, B; Chung, HG; Chung, HH; Kim, KM; Kim, SH; Jeong, WK; Kim, YK; Min, JH; Heo, JS; Han, IW; Shin, SH; Park, HC; Yu, JI; Park, JO; Kim, ST; Hong, JY; Lee, SH; Lee, KH; Lee, JK; Lee, KT; Jang, KT; Park, JK
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.11.031 Threshold dose-response association between smoking pack-years and the risk of gallbladder cancer: A nationwide cohort study Park, JH; Hong, JY; Han, K
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.22.00145 Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study Park, JH; Hong, JY; Han, K; Park, YS; Park, JO
    View PubMed
  • PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697 MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • J IMMUNOTHER CANCER 2022 10.1136/jitc-2022-005041 Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer Kwon, M; Kim, G; Kim, R; Kim, KT; Kim, ST; Smith, S; Mortimer, PGS; Hong, JY; Loembe, AB; Irurzun-Arana, I; Koulai, L; Kim, KM; Kang, WK; Dean, E; Park, WY; Lee, J
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.854 Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy Kim, R; Hong, JY; Lee, J; Kwon, GY; Jeong, BC; Park, SH
    View PubMed
  • THER ADV MED ONCOL 2022 10.1177/17588359221113266 The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma Kim, HS; Kim, CG; Hong, JY; Kim, IH; Kang, B; Jung, S; Kim, C; Shin, SJ; Choi, HJ; Cheon, J; Chon, HJ; Lim, HY
    View PubMed
  • BIOMEDICINES 2022 10.3390/biomedicines10071565 Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer Park, JS; Yu, JI; Lim, DH; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
    View PubMed
  • SCI REP-UK 2022 10.1038/s41598-022-14856-w Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease Park, JH; Hong, JY; Han, K; Kang, W; Park, JK
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.888755 Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis Yu, JI; Kang, W; Yoo, GS; Goh, MJ; Sinn, DH; Gwak, GY; Paik, YH; Choi, MS; Lee, JH; Koh, KC; Paik, SW; Hong, JY; Lim, HY; Park, B; Park, HC
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11688-w ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11592-3 Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • J ONCOL 2022 10.1155/2022/9714570 Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing Hyung, S; Han, B; Jung, J; Kim, ST; Hong, JY; Park, SH; Zang, DY; Park, JO; Park, YS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • J CANCER 2022 10.7150/jca.67050 Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial Kim, R; Ji, JH; Kim, JH; Hong, JY; Lim, HY; Kang, WK; Lee, J; Kim, ST
    View PubMed
  • GASTROENTEROLOGY 2022 10.1053/j.gastro.2021.09.070 Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study Park, JH; Han, K; Hong, JY; Park, YS; Hur, KY; Kang, G; Park, JO
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2021.12.027 Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study Park, JH; Han, K; Hong, JY; Park, YS; Park, JO
    View PubMed
  • GENOME MED 2022 10.1186/s13073-021-00995-8 Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial Hong, JY; Cho, HJ; Sa, JK; Liu, XQ; Ha, SY; Lee, T; Kim, H; Kang, W; Sinn, DH; Gwak, GY; Choi, MS; Lee, JH; Koh, KC; Paik, SW; Park, HC; Kang, TW; Rhim, H; Lee, SJ; Cristescu, R; Lee, J; Paik, YH; Lim, HY
    View PubMed
  • LIVER INT 2021 10.1111/liv.15102 Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma Cheon, J; Yoo, C; Hong, JY; Kim, HS; Lee, DW; Lee, MA; Kim, JW; Kim, I; Oh, SB; Hwang, JE; Chon, HJ; Lim, HY
    View PubMed
  • J CANCER RES CLIN 2021 10.1007/s00432-021-03781-6 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251 Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J
    View PubMed
  • CANCER MED-US 2021 10.1002/cam4.4259 Reducing tumor invasiveness by ramucirumab and TGF-beta receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model Lee, SY; Byeon, S; Ko, J; Hyung, S; Lee, IK; Li Jeon, N; Hong, JY; Kim, ST; Park, SH; Lee, J
    View PubMed
  • CANCER DISCOV 2021 10.1158/2159-8290.CD-21-0219 Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer Kwon, M; An, M; Klempner, SJ; Lee, H; Kim, KM; Sa, JK; Cho, HJ; Hong, JY; Lee, TY; Min, YW; Kim, TJ; Min, BH; Park, WY; Kang, WK; Kim, KT; Kim, ST; Lee, J
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/17588359211038478 Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer Hong, JY; Cho, HJ; Kim, ST; Park, YS; Shin, SH; Han, IW; Lee, JY; Heo, JS; Park, JO
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.06.052 Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population- based cohort study Park, JH; Hong, JY; Park, YS; Kang, GS; Han, K; Park, JO
    View PubMed
  • METABOLISM 2021 10.1016/j.metabol.2021.154848 Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study Park, JH; Hong, JY; Park, YS; Kang, G; Han, K; Park, JO
    View PubMed
  • J CANCER 2021 10.7150/jca.62853 When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer Kim, H; Kim, H; Lee, M; Kwon, M; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • FRONT IMMUNOL 2021 10.3389/fimmu.2021.701668 Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody Kim, N; Yu, JI; Lim, DH; Lee, J; Kim, ST; Hong, JY; Kang, WK; Jeong, WK; Kim, KM
    View PubMed
  • BRIT J RADIOL 2021 10.1259/bjr.20210352 Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer Cha1, DI; Song, KD; Ha, SY; Hong, JY; Hwang, JA; Ko, SE
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.03.024 Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study Park1, JH; Hong, JY; Kwon, M; Lee, J; Han, K; Han, IW; Kang, W; Park, JK
    View PubMed
  • EUR RADIOL 2021 10.1007/s00330-021-08094-3 Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer Cha1, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D
    View PubMed
  • CANCER MANAG RES 2021 10.2147/CMAR.S309092 Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma Lee1, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ
    View PubMed
  • ESMO OPEN 2021 10.1016/j.esmoop.2021.100049 Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG) Park1, HS; Kang, B; Chon, HJ; Im, HS; Lee, CK; Kim, I; Kang, MJ; Hwang, JE; Bae, WK; Cheon, J; Park, JO; Hong, JY; Kang, JH; Kim, JH; Lim, SH; Kim, JW; Kim, JW; Yoo, C; Choi, HJ
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • CANCERS 2021 10.3390/cancers13010059 Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses Park1, JS; Il Yu, J; Lim, D; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
    View PubMed
  • GENOME MED 2021 10.1186/s13073-021-00826-w Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial Kim1, ST; Sa, JK; Oh, SY; Kim, K; Hong, JY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • IN VIVO 2021 10.21873/invivo.12284 ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy Kim1, H; Kim, ST; Yoo, KH; Hong, JY; Park, YS; Lim, HY; Park, JO
    View PubMed
  • J CANCER 2021 10.7150/jca.49176 Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920965842 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
    View PubMed
  • CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02794-3 Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab Kim1, N; Yu, JI; Park, HC; Yoo, GS; Choi, C; Hong, JY; Lim, HY; Lee, J; Choi, MS; Lee, JE; Kim, K
    View PubMed
  • RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043 Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial Yu1, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH
    View PubMed
  • CANCER EPIDEM BIOMAR 2020 10.1158/1055-9965.EPI-20-0594 Obesity Has a Stronger Relationship with Colorectal Cancer in Postmenopausal Women than Premenopausal Women Chang1, JW; Shin, DW; Do Han, K; Jeon, KH; Yoo, JE; Cho, IY; Choi, YJ; Hong, JY
    View PubMed
  • GASTRIC CANCER 2020 10.1007/s10120-020-01124-x Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors Kim1, YY; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Sohn, I; Choi, D
    View PubMed
  • ANN SURG ONCOL 2020 10.1245/s10434-020-08408-7 Regional Lymph Node Metastasis of Scalp Angiosarcoma A Detailed Clinical Observation Study of 40 Cases Kang1, Y; Bae, J; Choi, S; Jang, KT; Yu, J; Hong, JY; Lim, SY; Jeong, HS
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00731-z Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma A Multicenter Retrospective Cohort Study Oh1, CR; Hong, JY; Kim, JH; Lee, JS; Kim, HS; Kim, TW; Ahn, JH; Kim, JE
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920926796 First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
    View PubMed
  • LIVER INT 2020 10.1111/liv.14496 Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events Yoo1, C; Byeon, S; Bang, Y; Cheon, J; Kim, JW; Kim, JH; Chon, HJ; Kang, B; Kang, MJ; Kim, I; Hwang, JE; Kang, JH; Lee, MA; Hong, JY; Lim, HY; Ryoo, BY
    View PubMed
  • Transl Cancer Res 2020 10.21037/tcr-19-1876 Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00713-1 Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients Kim1, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00706-0 Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
    View PubMed
  • ESMO OPEN 2020 10.1136/esmoopen-2020-000670 Clinical scoring system for the prediction of survival of patients with advanced gastric cancer Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J
    View PubMed
  • Genome Med 2020 10.1186/s13073-020-0717-8 Comprehensive pharmacogenomic characterization of gastric cancer Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-019-00691-z Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • LEUKEMIA LYMPHOMA 2020 10.1080/10428194.2019.1709831 Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP Kang1, J; Chae, H; Hong, JY; Yoon, DH; Kim, S; Park, JS; Lee, SW; Park, CS; Ryu, JS; Huh, J; Suh, C
    View PubMed
  • J ONCOL 2020 10.1155/2020/4659062 Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
    View PubMed
  • PLoS One 2019 10.1371/journal.pone.0215080 Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J
    View PubMed